PureTech Health plc Amends Akili, Inc. Filing

TL;DR

PureTech Health plc filed an update on their Akili, Inc. stake. Check the details.

AI Summary

PureTech Health plc, through its subsidiary PureTech Health LLC, has filed an amendment (Amendment No. 1) to its Schedule 13D concerning Akili, Inc. The filing, dated May 30, 2024, indicates a change in reporting regarding Akili, Inc. securities. PureTech Health plc is a company focused on pharmaceutical preparations, while Akili, Inc. is in the surgical and medical instruments sector.

Why It Matters

This amendment signals a potential shift in the relationship or holdings between PureTech Health plc and Akili, Inc., which could impact Akili's stock performance and strategic direction.

Risk Assessment

Risk Level: medium — Changes in 13D filings can indicate significant shifts in major shareholder intentions, potentially affecting stock price and company strategy.

Key Numbers

• 20240530 — Filing Date (Indicates the date of the amendment filing.)

Key Players & Entities

• PureTech Health plc (company) — Filing entity and parent company
• PureTech Health LLC (company) — Subsidiary of PureTech Health plc
• Akili, Inc. (company) — Subject company of the filing
• Bharatt Chowrira (person) — Contact person for PureTech Health plc

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securiti
• $0.4340 — ce per share of the Common Stock of (x) $0.4340 (the Offer Price); and (ii) the merger

Filing Documents

• d782979dsc13da.htm (SC 13D/A) — 45KB
• 0001193125-24-149863.txt ( ) — 46KB

of the Schedule 13D is hereby supplemented as follows

Item 4 of the Schedule 13D is hereby supplemented as follows: Merger Agreement On May 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the Merger Agreement) with Virtual Therapeutics Corporation, a Delaware corporation (Parent), and Alpha Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser). The Merger Agreement provides for, among other things: (i) the acquisition of all of the Issuers outstanding shares of Common Stock through a cash tender offer (the Offer) by Purchaser, for a price per share of the Common Stock of (x) $0.4340 (the Offer Price); and (ii) the merger of Purchaser with and into the Issuer (the Merger), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. Under the Merger Agreement, Parent is required to commence the Offer as promptly as practicable, and in any event no later than June 3, 2024. As further described in the Form 8-K filed by the Issuer on May 29, 2024 (the Merger 8-K), pursuant to the terms of the Merger Agreement, as of immediately prior to the effective time of the Merger (the Effective Time), by virtue of the Merger and without any action on the part of the holders of Common Stock, (i) each outstanding share of Common Stock of the Issuer, other than any shares of Common Stock held in the treasury of the Issuer or owned, directly or indirectly, by Parent or Purchaser, or by any stockholders of the Issuer who are entitled to and who properly exercise appraisal rights under Delaware law, will be converted into the right to receive the Offer Price. The Merger 8-K also describes the treatment of certain Issuer equity awards at the Effective Time pursuant to the Merger Agreement. Tender and Support Agreement In connection with the Issuers execution of the Merger Agreement, on May 29, 2024, PureTech Health LLC (PureTech Health) and certain other beneficial owners of Common Stock entered into Tender and Support Agreements (the Tender and Support Agre

of the Schedule 13D is hereby supplemented as follows

Item 6 of the Schedule 13D is hereby supplemented as follows: The information in Item 4 above relating to the Tender and Support Agreement entered into by PureTech Health in connection with the Merger and the transactions contemplated by the Merger Agreement is incorporated herein by reference. Item7. Materials to be Filed as Exhibits. Exhibit Number Description 6 Form of Tender and Support Agreement, dated May 29, 2024 by and among Virtual Therapeutics Corporation, Alpha Merger Sub, Inc. and PureTech Health LLC (among others) (incorporated by reference to Exhibit 99.1 of Akili, Inc.s Current Report on Form 8-K filed on May 29, 2024). 4

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : May 30, 2024 PureTech Health plc By: /s/ Bharatt Chowrira Name: Bharatt Chowrira Title: Chief Executive Officer PureTech Health LLC By: /s/ Bharatt Chowrira Name: Bharatt Chowrira Title: Chief Executive Officer 5

View Full Filing

View this SC 13D/A filing on SEC EDGAR